This inventor holds 5 USPTO granted patents and 4 EPO patents. Top assignee: Avexa Limited. Active years: 2012-2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2012-2014
Title: Neeranat Thienthong: Innovator in Pharmaceutical Compounds
Introduction
Neeranat Thienthong is a notable inventor based in Malvern, Australia. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for treating viral infections. With a total of 5 patents to his name, Thienthong's work is recognized for its potential impact on medical treatments.
Latest Patents
Thienthong's latest patents include innovative compounds that offer new methods for treating viral infections. One of his notable inventions is related to bicyclic pyrimidinones, which provides a compound of Formula I or a pharmaceutically acceptable derivative, salt, or prodrug thereof. This invention also outlines a method for the treatment or prophylaxis of viral infections by administering an effective amount of the compound. Additionally, he has developed imidazopyrimidines, which similarly provide a compound of formula (I) for treating viral infections, along with pharmaceutical compositions that incorporate these compounds.
Career Highlights
Neeranat Thienthong is currently associated with Avexa Limited, a company focused on developing innovative therapies. His work at Avexa has allowed him to explore and expand his research in pharmaceutical compounds, contributing to advancements in the treatment of viral infections.
Collaborations
Thienthong collaborates with notable colleagues, including Eric Dale Jones and David Ian Rhodes. Their combined expertise enhances the research and development efforts within their field.
Conclusion
Neeranat Thienthong's contributions to pharmaceutical innovations demonstrate his commitment to improving medical treatments for viral infections. His patents reflect a significant advancement in the field, showcasing the potential for new therapeutic options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile